The Inflation Reduction Act requires Medicare officials to set drug prices over the coming years. However, the law does not treat all medicines equally. The legislation subjects traditional “small molecule” drugs to price controls just nine years after FDA approval and subjects large-molecule “biologic” therapies to price controls after 13 years.
CAHC examines:
- What is the small-molecule penalty?
- How will the small-molecule penalty impact costs?
- How will the small molecule penalty impact patients?
- What can Congress do?